Major supermarket launches booze saving bonanza with 30% off Whispering Angel and viral ‘chicken wine'
The supermarket giant has just launched a Buy Six, Save 30% deal on over 20 bottles of rosé - which could save drinkers up to £38.70.
2
2
The corker of a deal is available in Morrisons from Tuesday and is sure to make booze-loving Brits raise a glass.
Punters can match any six bottles from the selected range.
Some of the top picks include the infamous Whispering Angel Cotes De Provence Rosé, usually costing £21.50, and the online sensation La Vieille Ferme Rosé, which sets drinkers back £8.50.
Morrisons also cut the price of its Market Street Sirloin Steaks - just in time for BBQ weather - until Monday May 5.
This was a separate deal from the Buy Six, Save 30% offer.
The alcohol bargain ideal will run until Saturday May 18, and is available online and in-store.
Customers can also pick up bottles from the Morrisons The Best range.
Must-try favourites include The Best Vinho Verde Rosé, which costs £8 and the same price The Best South African Pale Rosé.
The mega deal is opnly available for a limited time - so rosé-lovers need to hurry if they want to pick up cheaper bottles.
It comes after the supermarket was trialling a major change to its aisles by using robots to undertake a "crucial" supermarket task.
The retail giant will be the first in the UK to test "Tally" robots, designed by US tech company Simbe, which claim to be the world's first autonomous inventory bot.
Three towns in the north of England will experience the robots first, which "check that products on shelves are being displayed correctly and are legally compliant".
Morrisons technology manager Katherine Allanach told The Grocer: "It is a crucial but time-consuming task and so Tally aims to allow more time for colleagues to focus on customer service."
The retailer is the first in the UK to invest in Simbe's robot, which utilises AI and computer vision to independently move its way across store aisles.
And last month, the chain closed 16 of its sites as it pushed ahead with a major overhaul.
The Morrisons Daily convenience stores shut their doors permanently on April 16, following a decision announced last month.
However, one location in Haxby will remain open for a few more weeks, closing on May 14.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
4 hours ago
- Daily Mirror
Pension alert for under 65s as DWP data shows 7 in 10 Brits are taking risk
New figures have sparked concern about the number of people withdrawing pension funds early as one expert details how to do it safely New Department for Work and Pensions data has raised alarm bells over how Brits are tapping into their pension pots at younger ages. The statistics showed that seven in 10 people who took flexible payments from their pension since 2015 were younger than 65 years old. Lisa Picardo, Chief Business Officer UK at PensionBee, warned that early pension access could easily result in people "draining their pension pot before they reach retirement", especially during the current cost of living squeeze. However, she said it is possible to begin drawing your pension in your early 60s or even late 50s without jeopardising your retirement security if you stick to certain fundamental guidelines. The 2015 pension freedom reforms permitted individuals to tap into their pension from age 55. This currently sits 11 years ahead of state pension eligibility. And this gap is set to widen as the state pension age faces ongoing review and rises in step with life expectancy data. For those drawing their pensions at the first opportunity, this could risks their money falling short even before state pension payments kick in. To avoid this pitfall, Lisa said: "The key is planning ahead and withdrawing sustainably. "Work out how much you might need each year from your personal pension in addition to what's available from your State Pension, factor in inflation and tax, and consider leaving as much as possible invested to keep growing. Even small adjustments to how much and how often you withdraw can make a big difference to your future income in later life. "Most importantly, remember your pension needs to last a lifetime. It needs to be there to support you for the whole of your retirement, not just the early years, so pacing yourself can help you enjoy the journey without running out of fuel." Looking at the new DWP statistics, Lisa expressed some optimism for what lies ahead. She pointed out how the data appears to demonstrate "a maturing" in how those over 55 have used their retirement funds since 2015. The pensions specialist said: "Rather than people raiding their pots the moment they turn 55, we're seeing more sensible behaviour, and people are waiting until they're genuinely approaching, or are in retirement, before making significant withdrawals. This may be reflective of longer working lives, delayed retirements and increased longevity. "Back in 2016, people in their late fifties were the biggest users, taking 42% of all taxable withdrawals, followed by 28% in their early 60s, and 30% in the over 65 age category. Now the 55-59 group has dropped to just 26%, with a stable 28% in their early 60s, and 46% of taxable withdrawals from the over 65s."
Daily Mirror
5 hours ago
- Daily Mirror
FCA issues compensation warning to millions of car owners
FCA has warned that people are being targeted by scammers Millions of Brits are being urged to be aware of fraudsters posing as car finance lenders with fake compensation offers. The Financial Conduct Authority (FCA) has reported a recent surge in scammers attempting to extract personal details such as names, addresses, dates of birth and bank information by offering bogus compensation. This warning comes after the FCA's announcement regarding a potential car finance compensation scheme. However, the city watchdog is keen to stress that no such scheme is currently in place. The FCA has confirmed that car finance lenders are not contacting customers about compensation at this time. If you receive a call of this nature, the advice is to hang up immediately and refrain from sharing any personal information. Any scam calls or texts should be forwarded to 7726, reports the Daily Record. Many banks are now utilising the easy-to-remember 159 phone number service, which connects worried customers directly to their bank if they've received suspicious contact. Nisha Arora, director of special projects at the FCA, issued a stern warning: "We're aware of scammers calling people and posing as car finance lenders, offering fake compensation and asking for personal details. There is no compensation scheme in place yet. If anyone receives a call like this, hang up immediately and do not share any information." The FCA has recently revealed plans to consult on a compensation scheme. It previously stated that many motor finance firms were flouting rules and laws by failing to provide customers with necessary information about commission paid by lenders to car dealers who sold the loans. Car finance compensation in a nutshell Motor finance customers could be in line for a payout following the FCA's announcement that it will consult on an industry-wide compensation scheme. The FCA has said that many motor finance firms were not adhering to rules or laws by not providing customers with relevant information about commission paid by lenders to the car dealers who sold the loans. This follows a ruling by the Supreme Court on 1 August on cases where the FCA had intervened. While some motor finance customers won't receive compensation because in many instances commission payments were legal, the court ruled that in certain circumstances the failure to properly disclose commission arrangements could be deemed unfair and therefore unlawful, according to the FCA. The FCA estimates that most individuals are likely to receive less than £950 in compensation. The final total cost of any compensation scheme is estimated to be between a whopping £9 billion and £18 billion. The consultation is set to be launched by early October. If the compensation scheme gets the green light, the first payouts should be made in 2026. The FCA has reassured those who have already lodged complaints that they need not take any further action. If consumers suspect they weren't informed about commission and may have overpaid their car finance lender, they should lodge a complaint immediately. The FCA also emphasised that there's no need to employ a claims management company or law firm, which could eat into any compensation by as much as 30%. Consumer champion Martin Lewis recently advised his followers on X (formerly Twitter) that "there's no harm in putting a DIY complaint now to see if you had a Discretionary Commission Arrangement". The FCA is set to propose guidelines on how lenders should "consistently, efficiently and fairly" determine whether a customer is due compensation and the amount owed. The regulatory body will keep a close eye on firms' adherence to these rules and will take action against any non-compliance.
Daily Mail
6 hours ago
- Daily Mail
SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism
As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of Solvonis Therapeutics. Yet the current valuation of £23million doesn't tell the full story. Or perhaps it tells its own tale: that the Brits are blinkered, even oblivious to a story unfolding on the other side of the Atlantic that has real and positive implications for Solvonis. More on this later. First, it's probably worth refreshing ourselves as to what the company is and does. Quite simply, it is a biotech company that is developing potential treatments for illnesses such as alcohol abuse, post-traumatic stress disorder, and depression, where innovation and treatment options are sorely lacking. And they have been for a number of decades. It has four programmes, one in phase III, which on a more progressive and capital-deep market such as Nasdaq would in and of itself justify at least one additional nought to Solvonis' market capitalisation. Again, more on this later. Its lead drug is SNV-001, an experimental treatment being tested in advanced clinical trials for people with severe alcohol use disorder (AUD). It combines two approaches: a carefully controlled dose of ketamine (a dual anaesthetic and painkiller medicine that affects certain brain receptors) given by drip, and a course of cognitive behavioural therapy, or CBT, designed to specifically help prevent relapse. The aim is to see if using these together can help people stay off alcohol more effectively than either treatment alone. Early trial results for SNV-001 have been encouraging. In phase II testing, people given the treatment had 50 per cent fewer heavy drinking days compared to those who received a placebo. Even more striking, on average 86 per cent of participants stayed off alcohol for six months after treatment, while only 2 per cent had managed this before joining the trial. The results were so good that the UK Department of Health through the National Institute of Health and Care Research are co-funding the trial. Looking ahead, the company plans to seek what is called a mixed-full approval in both the UK and EU, which could mean up to 10 years of market exclusivity if successful. Its second asset is where the hidden value resides and where, I would contend, the UK investing public just isn't recognising the upside. Called SVN-002, it is an experimental treatment being developed in the much larger US alcohol addiction treatment market It uses esketamine, closely related to ketamine, and, crucially, a compound already being used in Johnson & Johnson's new blockbuster, Spravato, in nasal form, to combat treatment-resistant depression. Top marks if you made the link. Don't worry if you didn't; but pay attention at the back! So alike are the two compounds that Solvonis last month kicked off a process designed to provide scientific 'bridging' data linking SVN‑002 to Spravato. By referencing the existing drug, Solvonis aims to pursue the 505(b)(2) regulatory pathway, a route that allows companies to rely on existing data to streamline approval processes. Not only this, the company also hopes SVN-002 will be eligible under the same reimbursement codes as Spravato, potentially saving significant time and cost. Now, here's the eyes-on-stalk moment. Spravato is already generating annual revenues of more than $1billion and analysts believe this figure could actually peak at $5billion. However, its addressable market is a couple of million Americans with severe depression. Contrast this with the estimated 22 million people in the States who struggle badly with alcohol. As they say in the States, you do the math(s). American investors have not been slow to cotton on. Companies listed across there paddling in similar, or adjacent, pools, the likes of Atai Life Sciences, MindMed, GH Research and Compass Pathways, have been in lift-off mode. Meanwhile, pharma giant Abbvie is reported in the US business press last week to be preparing a $1billion offer for a privately owned-US peer of Solvonis, a company called Gilgamesh Pharmaceuticals. In other words, real buzz around the sector in the States that has so far been absent here in the UK, which is also reflected in valuations stateside, which are orders of magnitude larger than Solvonis. Atai, for example, has programmes barely emerged from phase I and carries a market capitalisation of more than $800million. That reflects America's greater understanding of not just biotech, but the potential of this new emerging area of treatment. Value inflexion points for companies such as Solvonis tend to come at the end of clinical studies – phase II usually, but also phase III. This is when large pharma is sufficiently emboldened to invest in the expensive process of follow-on studies, and/or pouring tens of millions of dollars into gaining regulatory sign-off. A licensing agreement of this type not only provides third-party validation of the work to date, it comes with financial kickers such as upfront and milestone payments. We already know that Solvonis has drafted in Pharma Ventures, a specialist in partnership and alliances of the sort outlined above, to shop SNV-001. So, one can safely assume conversations are taking place. It will be interesting to track the role in negotiations played by Solvonis chair Dennis Purcell. He is also a director of IGI, which recently cut a $1.9 billion deal with AbbVie, with $700million of that upfront. Okay, this was in the oncology arena, but Purcell has first-hand experience of going toe-to-toe with big pharma. And this will be crucial when talks hit the nitty-gritty phase. A recent research note penned by the team at Singers used the net present value of Solvonis' two clinical stage assets, allied to what it calls a 'risk-adjusted patient-based forecast', to come up with a 1.6p price target. So, what does all this mean? Well, it suggests Solvonis' share price of 0.37p may not reflect the company's true potential.
